U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H16N2
Molecular Weight 200.28
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TETRAHYDROZOLINE

SMILES

c1ccc2c(c1)CCCC2C3=NCCN3

InChI

InChIKey=BYJAVTDNIXVSPW-UHFFFAOYSA-N
InChI=1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)

HIDE SMILES / InChI
Tetrahydrozoline is an alpha adrenergic receptor agonist, which is used in form of nasal solution or spray (Tyzin) for decongestion of nasal and nasopharyngeal mucosa.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2095203
Sources: www.ncbi.nlm.nih.gov/pubmed/18259967
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TYZINE

Approved Use

Tyzine Nasal Solution is indicated for decongestion of nasal and nasopharyngeal mucosa.

Launch Date

3.12768004E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.218 ng/mL
2 drop 4 times / day multiple, ocular
dose: 2 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
TETRAHYDROZOLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.46 ng × h/mL
2 drop 4 times / day multiple, ocular
dose: 2 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
TETRAHYDROZOLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6 h
2 drop 4 times / day multiple, ocular
dose: 2 drop
route of administration: Ocular
experiment type: MULTIPLE
co-administered:
TETRAHYDROZOLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
7500 ug single, oral
Overdose
Dose: 7500 ug
Route: oral
Route: single
Dose: 7500 ug
Sources:
healthy, 16 years
n = 1
Health Status: healthy
Age Group: 16 years
Sex: M
Population Size: 1
Sources:
Other AEs: Sinoatrial node dysfunction...
Other AEs:
Sinoatrial node dysfunction (1 patient)
Sources:
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Other AEs: Bradycardia, Hypertension...
Other AEs:
Bradycardia (2 patients)
Hypertension (1 patient)
Gasping (2 patients)
Sources:
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Other AEs: Hypotonia...
Other AEs:
Hypotonia (1 patient)
Sources:
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Condition: mild fever
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Other AEs: Apnea...
Other AEs:
Apnea (1 patient)
Sources:
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Other AEs: Hypothermia, Bradycardia...
Other AEs:
Hypothermia (1 patient)
Bradycardia (1 patient)
Hypotension (1 patient)
Miosis (1 patient)
Lethargy (1 patient)
Mucous membrane disorder (NOS) (1 patient)
Bowel sounds decreased (1 patient)
Chest pain (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Sinoatrial node dysfunction 1 patient
7500 ug single, oral
Overdose
Dose: 7500 ug
Route: oral
Route: single
Dose: 7500 ug
Sources:
healthy, 16 years
n = 1
Health Status: healthy
Age Group: 16 years
Sex: M
Population Size: 1
Sources:
Hypertension 1 patient
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Bradycardia 2 patients
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Gasping 2 patients
0.3 mg/kg single, oral
Overdose
Dose: 0.3 mg/kg
Route: oral
Route: single
Dose: 0.3 mg/kg
Sources:
healthy, 20 months-2 years
n = 2
Health Status: healthy
Age Group: 20 months-2 years
Sex: M+F
Population Size: 2
Sources:
Hypotonia 1 patient
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Apnea 1 patient
250 ug 3 times / day multiple, oral
Overdose
Dose: 250 ug, 3 times / day
Route: oral
Route: multiple
Dose: 250 ug, 3 times / day
Sources:
unhealthy, 25 days
n = 1
Health Status: unhealthy
Condition: mild fever
Age Group: 25 days
Sex: M
Population Size: 1
Sources:
Bowel sounds decreased 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Bradycardia 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Chest pain 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Hypotension 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Hypothermia 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Lethargy 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Miosis 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Mucous membrane disorder (NOS) 1 patient
15000 ug single, oral
Overdose
Dose: 15000 ug
Route: oral
Route: single
Dose: 15000 ug
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Transdermal penetration of vasoconstrictors--present understanding and assessment of the human epidermal flux and retention of free bases and ion-pairs.
2003 Feb
[The tolerability of nasal drugs with special regard to preservatives and physico-chemical parameters].
2003 Nov
Sinoatrial node arrest following tetrahydrozoline ingestion.
2004 Oct
[Drug administration in newborns. Is clinical experience enough?].
2006 Apr
Ophthalmic delivery systems based on drug-polymer-polymer ionic ternary interaction: in vitro and in vivo characterization.
2006 Jan
Antagonism by imidazoline-type drugs of muscarinic and other receptors in the guinea-pig ileum.
2006 Jul
Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline.
2008 Feb
Naloxone use in a newborn with apnea due to tetrahydrozoline intoxication.
2010 Jun
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Tetrahydrozoline (Visine®) concentrations in serum and urine during therapeutic ocular dosing: a necessary first step in determining an overdose.
2011 Nov
Patents

Sample Use Guides

Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Solution: It is recommended that 2 to 4 drops be instilled in each nostril as needed, never more often than every three hours. Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Spray: It is recommended to squeeze quickly and firmly three or four times the spray in each nostril as needed, never more often than every three hours. Children 2 to 6 Years of Age, Tyzine 0.05 % Pediatric Nasal Drops: It is recommended that 2 to 3 drops be instilled in each nostril as needed, and never more often than every three hours.
Route of Administration: Nasal
In Vitro Use Guide
Rat and rabbit aortae were treated with tetrahydrozoline at concentrations from 10(-7) to 10(-5) M to determine the drug relative efficacy. Emax value was 0.51 for the rabbit aortae and 0 for the rat aortae.
Name Type Language
TETRAHYDROZOLINE
HSDB   MI   VANDF  
Common Name English
TETRYZOLINE [INN]
Common Name English
1H-IMIDAZOLE, 4,5-DIHYDRO-2-(1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL)-
Systematic Name English
CALTHEON
Brand Name English
TETRAHYDROZOLINE [VANDF]
Common Name English
TETRAHYDROZOLINE [HSDB]
Common Name English
TETRAHYDROZOLINE [MI]
Common Name English
TETRYZOLINE [WHO-DD]
Common Name English
TETRYZOLINE
INN   WHO-DD  
INN  
Official Name English
Classification Tree Code System Code
WHO-VATC QS01GA02
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
WHO-ATC R01AB03
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
NCI_THESAURUS C29709
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
WHO-VATC QR01AA06
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
WHO-VATC QS01GA52
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
WHO-VATC QR01AB03
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
WHO-ATC S01GA02
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
WHO-ATC S01GA52
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
WHO-ATC R01AA06
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
Code System Code Type Description
INN
519
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
DRUG BANK
DB06764
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
DRUG CENTRAL
3591
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
MERCK INDEX
M10634
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
201-522-3
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
WIKIPEDIA
TETRAHYDROZOLINE
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
HSDB
7471
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
CAS
84-22-0
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
ChEMBL
CHEMBL1266
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
EPA CompTox
84-22-0
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
PUBCHEM
5419
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
RXCUI
37935
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY RxNorm
FDA UNII
S9U025Y077
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
EVMPD
SUB10955MIG
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY
NCI_THESAURUS
C61967
Created by admin on Sat Jun 26 15:15:54 UTC 2021 , Edited by admin on Sat Jun 26 15:15:54 UTC 2021
PRIMARY